<unk>  is indicated for the treatment of metachromatic leukodystrophy (MLD) characterized by biallelic mutations in the arysulfatase A (ARSA) gene leading to a reduction of the ARSA enzymatic activity in children with late infantile or early juvenile forms, without clinical manifestations of the disease; and in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
Atidarsagene autotemcel
Bald's eyesalve
Eyepatch
SpyCatcher
Eyeborg
InBev-Baillet Latour Fund
Zebra print ribbon
Hobcart